Navigation Links
Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference

l Cancer Trial

To date, eight patients have been dosed in this trial, of which seven have stabilized disease. Two of the seven patients have tumor shrinkage, one of 40% (partial response according to RECIST) and one of 15%. The patients have experienced no increase in drug-related toxicity. The Simon two-stage designed study is an open-label, multi-center trial of DAVANAT(R) in combination with 5-FU in a regimen with Avastin(R) and leucovorin in up to 50 patients with locally advanced, unresectable or metastatic colorectal cancer and who are unable to tolerate intensive chemotherapy. The primary objectives of the trial are tumor shrinkage and progression-free survival. Six sites are actively recruiting patients. Additional sites are expected to be active shortly.

Phase II, First Line, Biliary Cancer Trial

To date, five patients have been dosed in this trial, of which four have stabilized disease. One patient has 35% tumor shrinkage. The patients have experienced no increase in drug-related toxicity. A cholangiocarcinoma (bile duct cancer) patient from the Phase I trial remained on study for 13 months, far exceeding expectations. The Simon two-stage designed study is an open-label, multi-center trial to evaluate the efficacy and safety of DAVANAT(R) in combination with 5-FU in up to 42 patients. The primary objectives are complete/partial tumor response (RECIST) and progression-free survival. Three sites are actively recruiting patients. Three additional sites are expected to be active shortly.

Additional information on these two trials and participating sites can be found at www.clinicaltrials.gov website, key word: DAVANAT(R).

About DAVANAT(R)

DAVANAT(R), the Company's lead drug candidate, is a polysaccharide (carbohydrate polymer) composed of mannose and galactose (galactomannan). The Company believes DAVANAT(R)'s mechanism of action is based upon binding to lectins on the cell surface. It is theorized that DAVANAT(R) targ
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... today, which integrates with HealthKit in iOS 8 and ... with their doctors. The app harnesses native iOS technologies ... patients to maintain a robust connection with their doctors ... wearable health devices and the data they collect is ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... Neb., May 15 Creighton Medical Laboratories, based at ... announced today that it has become the first clinical ... testing method for cancer. The method, called SNP array ... to study cancer for several years. However, Creighton Medical ...
... Case Demonstrating RenalGuard To Be PresentedFRANKLIN, Mass., May ... PLCSF), a company focused on innovative cardiac and ... will demonstrate its RenalGuard System(TM) at EuroPCR, the ... Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 2PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 4
(Date:9/30/2014)... and cardiac muscles contain few stem cells, heart ... heart attack. Now Tel Aviv University researchers are ... tissue engineering. , Dr. Tal Dvir and his ... Biotechnology, Department of Materials Science and Engineering, and ... sophisticated micro- and nanotechnological tools ranging in ...
(Date:9/30/2014)... 2014 A new report launched today by ... Longitudinal Study on Ageing) conducted by academics from ... Dublin, Ireland, has highlighted the serious, complex and ... disability population. , The IDS-TILDA study is the ... the only one in the world with the ...
(Date:9/30/2014)... MyServer2Go.com made an announcement recently that ... this year for its quality VPS solution, reliable support ... MyServer2Go.com is a professional and targeted website which reviewed ... announcement will help webmasters find the best VPS hosting ... http://www.arvixe.com ) is one of the fastest-growing and most ...
(Date:9/30/2014)... Wellington, New Zealand (PRWEB) September 30, 2014 ... offers the potential to improve breast cancer risk ... risk, according to a study published in Breast ... article, “Digital mammographic density and breast cancer risk: ... methods,” demonstrates a strong connection between breast density ...
(Date:9/30/2014)... home surrounded by loved ones comes too late for ... change the process so that more patients may die ... the Frances Payne Bolton School of Nursing at Case ... million grant from the National Institute of Nursing Research ... Aggressiveness of End of Life Cancer Care," will contribute ...
Breaking Medicine News(10 mins):Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 4Health News:Arvixe Is Named Best VPS Hosting by MyServer2Go.com 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:CWRU researchers receives $2.06 million to study how patients make end-of-life decisions 2
... Attention Deficit Hyperactivity Disorder, or ADHD, is widely recognized by ... in place. But as many as six percent of all ... Demonstrating a lack of refined motor skills, children with DCD ... staying organized at school. They appear to be uncoordinated ...
... , SUNDAY, April 3 (HealthDay News) -- There,s a ... women, but it depends on their body weight, researchers report. ... smokers who were not obese, but this strong association was ... study. Researchers analyzed data from 76,628 women, aged 50 ...
... test believe it is the most accurate yet in ... asbestos. Study results of this aptamer proteomic technology were ... April 2-6. In a blinded test performed under ... Research Network Biomarker Discovery Lab, the proteomic assay could ...
... NYU Langone Medical Center have investigated a novel protein ... can accurately identify proteins secreted from cancerous tumors caused ... American Association for Cancer Research 102nd Annual Meeting 2011 ... performed under the sponsorship of the National Cancer Institute,s ...
... Amanda Gardner HealthDay Reporter , SUNDAY, April 3 ... a new valve in a damaged heart is as good ... risk of stroke, researchers reported Sunday. Transcatheter ... in the heart via an artery in the leg or ...
... Reporter , SATURDAY, April 2 (HealthDay News) -- Men taking ... the risk of a heart attack or stroke, a small, ... 5 percent increase in the thickness of the large artery ... to the brain, the researchers from Emory University found. ...
Cached Medicine News:Health News:Clumsy kids who don't 'grow out of it' 2Health News:Study Links Smoking, Breast Cancer in Older Women 2Health News:Protein test detects early-stage, asbestos-related pulmonary cancer 2Health News:New test detects early-stage, asbestos-related pulmonary cancer 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 3Health News:Study Hints at Link Between Antidepressants and Heart Trouble 2Health News:Study Hints at Link Between Antidepressants and Heart Trouble 3
... A lower cost alternative to Equalizers, the ... transfers between two different vessel configurations. With the ... can be quickly and easily adjusted for test ... Ergonomic Design for Unparalleled Comfort Pick ...
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
Packaging: Set includes: Eight-channel pipette (10.8 mm with 0.5-5.0 μl capacity) 25 PrismStrip 96 tips with rack 2 FlexPlates with a holder...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: